Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Andrew BlauveltCarle F PaulPeter Cornelis Maria van de KerkhofR B WarrenA B GottliebR G LangleyF BrockC ArendtM BoehnleinM LebwohlKristian ReichPublished in: The British journal of dermatology (2020)
No new safety signals were identified compared with previously reported data. Risk did not increase with longer or higher CZP exposure.